Role of XPC, XPD, XRCC1, GSTP genetic polymorphisms and Barrett's esophagus in a cohort of Italian subjects. A neural network analysis

Clinical and Experimental Gastroenterology

Volumn 5, Issue 1, 2012, Pages 159-166

  Tarlarini, Claudia ^a   Penco, Silvana ^a   Conio, Massimo ^b   Grossi, Enzo ^c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b GENERAL HOSPITAL   (Italy)

^c Bracco Imaging SpA   (Italy)

Author keywords

Barrett's esophagus; XPC XPD genetic polymorphisms; XRCC1 GSTP genetic poly morphisms

Indexed keywords

GLUTATHIONE TRANSFERASE P1; XERODERMA PIGMENTOSUM GROUP C PROTEIN; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADULT; ARTICLE; ARTIFICIAL NEURAL NETWORK; BARRETT ESOPHAGUS; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ETHNIC GROUP; FEMALE; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GLUTATHIONE TRANSFERASE P1 GENE; HIGH RISK PATIENT; HUMAN; ITALIAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PHENOTYPE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; XERODERMA PIGMENTOSUM GROUP C GENE; XERODERMA PIGMENTOSUM GROUP D GENE; XRCC1 GENE;

EID: 84866009770     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S32610     Document Type: Article

References (41)

1. Barbera M, Fitzgerald RC. Cellular mechanisms of Barrett's esophagus development. Surg Oncol Clin N Am. 2009;18(3):393-410.
2. di Pietro M, Fitzgerald RC. Barrett's oesophagus: an ideal model to study cancer genetics. Hum Genet. 2009;126(2):233-246.
3. Shaheen NJ, Crosby MA, Bozymski EM, Sandler RS. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterol-ogy. 2000;119(2):333-338.
4. Yousef F, Cardwell C, Cantwell MM, Galway K, Johnston BT, Murray L. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and meta-analysis. Am J Epidemiol. 2008;168(3):237-249.
5. Wong NA, Wilding J, Bartlett S, et al. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc Natl Acad Sci U S A. 2005; 102(21):7565-7570.
6. Pondugula K, Wani S, Sharma P. Barrett's esophagus and esophageal adenocarcinoma in adults: long-term GERD or something else? Curr Gastroenterol Rep. 2007;9(6):468-474.
7. Kruijshaar ME, Siersema PD, Janssens AC, Kerkhof M, Steyerberg EW, Essink-Bot ML; CYBAR Study Group. Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc. 2007;65(1):26-30.
8. Vaezi MF, Richter JE. Role of acid and duodenogastroesophageal refux in gastroesophageal refux disease. Gastroenterology. 1996;111(5): 1192-1199.
9. Wong A, Fitzgerald RC. Epidemiologic risk factors for Barrett's esophagus and associated adenocarcinoma. Clin Gastroenterol Hepatol. 2005;3(1):1-10.
10. Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007;133(1):34-41.
11. Edelstein ZR, Farrow DC, Bronner M P, Rosen SN, Vaughan TL. Central adiposity and risk of Barrett's esophagus. Gastroenterology. 2007;133(2):403-411. Epub May 21, 2007.
12. Robertson E V, Jankowki JA. Genetics of gastroesophageal cancer: paradigms, paradoxes, and prognostic utility. Am J Gastroenterol. 2008; 103(2):443-449. Epub October 9, 2007.
13. van Lieshout EM, Roelofs HM, Dekker S, et al. Polymorphic expression of the glutathione S-transferase P1 gene and its susceptibility to Barrett's esophagus and esophageal carcinoma. Cancer Res. 1999;59(3): 586-589.
14. Abbas A, Delvinquiere K, Lechevrel M, et al. GSTM1, GSTT1, GSTP1 and CYP1A1 genetic polymorphisms and susceptibility to esophageal cancer in a French population: different pattern of squamous cell carcinoma and adenocarcinoma. World J Gastroenterol. 2004;10(23):3389-3393.
15. Hao B, Wang H, Zhou K, et al. Identification of genetic variants in base excision repair pathway and their associations with risk of esophageal squamous cell carcinoma. Cancer Res. 2004;64(12):4378-4384.
16. Casson AG, Zheng Z, Evans SC, Veugelers PJ, Porter GA, Guernsey DL. Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma. Carcinogenesis. 2005;26(9): 1536-1541.
17. Shen H, Xu Y, Qian Y, et al. Polymorphisms of the DNA repair gene XRCC1 and risk of gastric cancer in a Chinese population. Int J Cancer. 2000; 88:601-606.
18. Grossi E, Filiberti R, Blanchi S, et al. W1995 artificial neural networks allow good discrimination of Barrett's esophagus from GERD on the basis of biographic, clinical history, symptoms and lifestyle habits. Gastroenterology. 2009;136(5):A-769.
19. Lee YL, Lin YC, Lee YC, Wang JY, Hsiue TR, Guo YL. Glutathione S-transferase P1 gene polymorphism and air pollution as interactive risk factors for childhood asthma. Clin Exp Allergy. 2004;34(11):1707-1713.
20. Grossi E. Artifcial Adaptive Systems and predictive medicine: a revolutionary paradigm shift. Immun Ageing. 2010;7(Suppl 1):S3.
21. Grossi E, Buscema M. Introduction to artificial neural networks. Eur J Gastroenterol Hepatol. 2007;19(12):1046-1054.
22. Rumelhart DE, McClelland JL. Parallel Distributed Processing: Explorations in the Microstructure of Cognition. Vol 1. Cambridge, MA: Foundations, MIT Press; 1986.
23. Buscema M, Grossi E, Intraligi M, Garbagna N, Andriulli A, Breda M. An optimized experimental protocol based on neuro-evolutionary algorithms application to the classification of dyspeptic patients and to the prediction of the effectiveness of their treatment. Artif Intell Med. 2005;34(3):279-305.
24. Buscema M. Genetic Doping Algorihm (GenD): theory and applications. Expert Systems. 2004;21(2):63-79.
25. Buscema M, Capriotti M, Bergami F, Babiloni C, Rossini P, Grossi E. The implicit function as squashing time model: a novel parallel nonlinear EEG analysis technique distinguishing mild cognitive impairment and Alzheimer's disease subjects with high degree of accuracy. Comput Intell Neurosci. 2007:Article ID 35021, 15 pages.
26. Jacobson BC, Giovannucci EL, Fuchs CS. Smoking and Barrett's esophagus in women who undergo upper endoscopy. Dig Dis Sci. 2011; 56(6):1707-1717.
27. Li X, Galipeau PC, Sanchez CA, et al. Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in Barrett's esophagus neoplastic progression. Cancer Prev Res (Phila). 2008;1(6):413-423.
28. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature. 2001;411(6835):366-374.
29. Benhamou S, Sarasin A. Variability in nucleotide excision repair and cancer risk: a review. Mutat Res. 2000;462(2-3):149-158.
30. Berwick M, Vineis P. RESPONSE re: markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst. 2000;92(18):874-897.
31. López-Cima M F, González-Arriaga P, Garcia-Castro L, et al. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC Cancer. 2007;7:162.
32. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001;291(5507):1284-1289.
33. Kadioglu E, Sardas S, Ergun M, Unal S, Karakaya AE. The role of oxidative DNA damage, DNA repair, GSTM1, SOD2 and OGG1 polymorphisms in individual susceptibility to Barrett's esophagus. Toxicol Ind Health. 2010;26(2):67-79.
34. Zienolddiny S, Campa D, Lind H, et al. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis. 2006; 27(3):560-567.
35. Sturgis EM, Zheng R, Li L, et al. XPD/ERCC2 polymorphisms and risk of head and neck cancer: a case-control analysis. Carcinogenesis. 2000;21(12):2219-2223.
36. Terry MB, Gammon MD, Zhang FF, et al. Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13(12):2053-2058.
37. Frosina G. Commentary: DNA base excision repair defects in human pathologies. Free Radic Res. 2004;38(10):1037-1054.
38. Wilson DM 3rd, Sofnowski TM, McNeill DR. Repair mechanisms for oxidative DNA damage. Front Biosci. 2003;8:d963-d981.
39. Brabender J, Lord RV, Wickramasinghe K, et al. Glutathione S-transferase-pi expression is downregulated in patients with Barrett's esophagus and esophageal adenocarcinoma. J Gastrointest Surg. 2002; 6(3):359-367.
40. Lai LA, Kostadinov R, Barrett MT, et al. Deletion at fragile sites is a common and early event in Barrett's esophagus. Mol Cancer Res. 2010; 8(8):1084-1094.
41. Wang X, Ouyang H, Yamamoto Y, et al. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell. 2011;145(7):1023-1035.